Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Has results × GSK2110183 × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

Cyclophosphamide 142 pembrolizumab 125 Nivolumab 113 Carboplatin 98 Dexamethasone 92 Rituximab 91 Paclitaxel 87 Gemcitabine 84 Lenalidomide 74 Cytarabine 73 Radiotherapy 71 Cisplatin 70 Bevacizumab 63 Etoposide 62 fludarabine phosphate 57 fludarabine 55 Bortezomib 54 Ipilimumab 53 Docetaxel 53 Prednisone 49 Doxorubicin 48 Temozolomide 47 Everolimus 46 Erlotinib Hydrochloride 46 Fluorouracil 44 Capecitabine 43 Calcium Dobesilate 43 Azacitidine 43 Filgrastim 42 Melphalan 41

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01653912 2018-04-02

Dose-finding Study in Platinum-Resistant Ovarian Cancer

Accenture

Phase 1/2 Completed

59 enrolled 18 charts

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡